Company Encyclopedia
View More
name
VanEck Biotech ETF
BBH.US
News
View More

argenex SE (NASDAQ:ARGX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Argenex SE (NASDAQ:ARGX) has received a "Moderate Buy" consensus rating from 24 brokerages, with a 12-month target price of $907.67. Analysts have varied ratings, including hold, buy, and strong buy. Recent price targets range from $850 to $1,070. Institutional investors own 60.32% of the stock. Argenex reported $4.40 EPS for the quarter, surpassing estimates, with $1.12 billion revenue. The company develops therapies for autoimmune diseases globally.

Market Beat·
US
ARGX
-1.62%
Market Beat·
US
ARGX
-1.62%

Vertex Pharmaceuticals: Promising Advancements in Kidney Disease Treatments Drive Buy Rating

Goldman Sachs analyst Salveen Richter maintains a Buy rating on Vertex Pharmaceuticals, citing promising advancements in kidney disease treatments, particularly the dual APRIL/BAFF inhibitor, povetacicept. The treatment shows clinical success and potential for accelerated approval by 2026. Vertex's strategic execution in kidney disease and immunology supports the positive outlook, with additional growth expected from upcoming Phase 3 and Phase 2 trials. Citi also maintains a Buy rating with a $575 price target.

Tip Ranks·
US
VRTX
-0.41%
Tip Ranks·
US
VRTX
-0.41%

Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals announced promising Phase 1/2 trial results for Lynozyfic in newly diagnosed multiple myeloma patients. The trial showed impressive efficacy, with 70% achieving very good partial response or better, and 95% of evaluable patients achieving minimal residual disease negative status. These findings were presented at the American Society of Hematology Annual Meeting, highlighting Lynozyfic's potential for durable outcomes in early treatment lines.

rttnews·
US
REGN
-0.61%
rttnews·
US
REGN
-0.61%

Regeneron Hosts Virtual Investor Event on Multiple Myeloma Program

Regeneron Pharmaceuticals Inc. will host a virtual investor event on December 10 to discuss its multiple myeloma program. The event is part of the 'Regeneron Roundtable' series, highlighting the company's investigational pipeline. Participants can register via Regeneron's website, and a replay will be available for 30 days. This AI-generated news brief is for informational purposes only and not financial advice.

Reuters·
US
REGN
-0.61%
Reuters·
US
REGN
-0.61%

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment | REGN Stock News

Regeneron Pharmaceuticals announced promising results from the Phase 1/2 LINKER-MM4 trial of Lynozyfic™ (linvoseltamab) in newly diagnosed multiple myeloma patients. The trial showed impressive efficacy across all dose groups, with a VGPR+ rate of ≥70% and 95% achieving MRD negative status. The results suggest Lynozyfic's potential as a foundational treatment in frontline regimens. Regeneron will discuss its multiple myeloma program in a virtual investor event on December 10.

StockTitan·
US
REGN
-0.61%
StockTitan·
US
REGN
-0.61%
© 2025 Longbridge｜Disclaimer